Summary: In spite of over 40 years of clinical use of 6-mercaptopurine, many aspects of complex pharmacology and metabolism of this drug remain unclear. It is thought that 6-mercaptopurine is oxidized to 6-thiouric acid through 6-thioxanthine or 8-oxo-6-mercaptopurine by one of two molybdenum hydroxylases, xanthine oxidase (XO), however, the role of other molybdenum hydroxylase, aldehyde oxidase (AO), in the oxidation of 6-mercaptopurine and possible interactions of AO substrates and inhibitors has not been investigated in more details. In the present study, the role of AO and XO in the oxidation of 6-mercaptopurine has been investigated. 6-Mercaptopurine was incubated with bovine milk xanthine oxidase or partially puriˆed guinea pig liver molybdenum hydroxylase fractions in the absence and presence of XO and AO inhibitor W substrates, and the reactions were monitored by spectrophotometric and HPLC methods. According to the results obtained from the inhibition sudies, it is more likely that 6-mercaptopurine is oxidized to 6-thiouric acid via 6-thioxanthine rather than 8-oxo-6-mercaptopurine. Thê rst step which is the rate limiting step is catalized solely by XO, whereas both XO and AO are involved in the oxidation of 6-thioxanthine to 6-thiouric acid.
Introduction
6-Mercaptopurine (6-MP) is a thiopurine drug in which carbon 6 of purine has been substituted with a sulphur-containing group (Fig. 1 ). This drug with methotrexate are the drugs of choice in the treatment of childhood acute lymphoblastic leukemia, especially in those cases where prolonged duration of remission is required. [1] [2] [3] 6-MP together with its prodrug azathioprine are used as immunomodulatory agents in the treatment of in‰ammatory bowel disease. 4 ) Although 6-MP has been used for over 40 years, many aspects of its complex pharmacology and metabolism remain unclear. 1, 5) However, it has been suggested that in the cell, 6-MP isˆrst converted to thioinosinic acid, by hypoxanthine-guanine phosphoribosyl-transferase and then metabolised to thioguanine ribonucleotide and deoxyribonucleotide; incorporation of these compounds into RNA and DNA results in the antitumour eŠect of the drug. [6] [7] [8] 6 -MP after administration, may enter into either anabolic or catabolic metabolic pathways. 1, 7) The anabolic pathway is responsible for conversion of 6-MP to its active form, whereas the drug is degraded to inactive forms in the catabolic pathway via two enzymatic sequences. Theˆrst route is thought to involve the initial oxidation of 6-MP to 8-oxo-6-mercaptopurine followed by conversion to 6-thiouric acid. 1, 9) However, Zimm et al. have identiˆed 6-thioxanthine in the urine samples of some patients who received 6-MP by intravenous infusion which may indicate that 6-MP is converted to 6-thiouric acid via 6-thioxanthine. 6) 6-Methylmercapto-8-hydoxypurine has been identiˆed by others 10) as a major metabolite of 6-MP in plasma during intravenous administration. The oxidative inactivation of 6-MP has been attributed to xanthine oxidase (XO) activity in intestinal mucosa and liver. 1, 6) The presence of large amounts of this enzyme in the liver has been considered as a major reason for the low Fig. 1 . Proposed metabolic pathways for 6-mercaptopurine. 1, 5) bioavailability of 6-MP.
11) Accordingly, adminstration of methotrexate as an inhibitor of XO alongside with 6-MP has been used to increase the bioavailabity of the later drug. 11, 12) The Km value for the oxidation of 6-MP by calf liver and bovine milk xanthine oxidase (BMXO) is 20-30 mM. 13, 14) 6-MP is also a substrate for rabbit liver aldehyde oxidase (AO) with a reported Km of 1.6 mM.
15) The second catabolic pathway for 6-MP is methylation of the sulphur atom catalysed by thiopurine methyltransferase. 6-Methylmercaptopurine then undergoes oxidation at position 8. Although the oxidation at 8 position could be catalysed by XO and W or AO, 1) there is some indirect evidence indicative of the signiˆcant role of AO in 8-hydroxylation. 16) The results obtained from in vitro studies are also controversy. Thiouric acid, 8-hydroxy-6-mercaptopurine and 6-methylmercaptopurine have been identiˆed after incubation of 500 mM 6-MP with human liver cytosol. 17) To our knowledge, there is not a direct and comparative study of the involvement of molybdenum hydroxylases in this oxidative reactions. Furthermore, 8-hydroxy-6-mercaptopurine 1, 9, 10, 17) and 6-thioxanthine 6, 10) have been suggested to be the intermediate in the conversion of 6-MP to 6-thiouric acid. Therefore, in the present study, the oxidation of 6-MP by BMXO and partially puriˆed guinea pig liver molybdenum hydroxylases have been investigated. Guinea pig liver enzyme fraction was chosen because of its resemblance to human liver AO. 18, 19) 
Materials and Methods
Chemicals: Phthalazine and phenanthridine were purchased from Aldrich Chemical Company (UK). 6-MP, 6-thioxanthine, allopurinol, menadione, isovanillin, xanthine, hypoxanthine, uric acid and BMXO (Grade I) were obtained from Sigma Chemical Company (UK).
Animals: Mature male or female Dunkin-Hartley guinea pigs (400-600 g, University of Bradford, Bradford, UK) were used in this study. Animals were housed 6-mercaptopurine Metabolism by Molybdenum Hydroxylases in pairs in plastic cages, maintained in controlled temperature (18-199 C) , humidity (50z), and lighting cycle of 07:00-19:00 hours light, 19:00-07:00 hours dark. They were fed with a standard laboratory diet and allowed food and water ad libitum.
Preparation of molybdenum hydroxylase fractions: The guinea pigs were killed between 9.00 am and 10.00 am by cervical dislocation, their livers were immediately excised, placed in ice-cold isotonic potassium chloride solution (1.15z KCl w W v) containing 0.1 mM EDTA and the gall bladder and excess fat were removed. Partially puriˆed molybdenum hydroxylase fractions were prepared from liver homogenates by heat treatment and ammonium sulphate precipitation according to the method of Johnson et al. 20) Theˆnal EDTA suspension was stored in liquid nitrogen until required.
Spectrophotometric measurement of enzyme activity: All spectrophotometric determinations were carried out at 379 C using a Shimadzu 2101 UV W VIS spectrophotometer (Shimadzu Scientiˆc Instruments Inc., Columbia USA) which was computer controlled by the Shimadzu UV-210 personal spectroscopy software package with additional kinetics software. The instrument was connected to a Pye-Unicam cell temperature control unit. The cuvettes used had a path length of 1 cm and total cuvette volume was constant at 3.0 mL. 6-MP, 6-thioxanthine and hypoxanthine (100 mM) was separately incubated with BMXO or partially puriˆed guinea pig liver fractions in Sorenson's phosphate buŠer pH 7.0 containing 0.1 mM EDTA at 379 C and the enzymatic oxidation of each compound was monitored spectrophotometrically by repetitive scanning of the UV spectra between 190-400 nm up to 60 min. Theˆnal spectrum was compared with that of 6-thioxanthine and those reported 13) for 8-oxo-6-MP and 6-thiouric acid as authentic samples were not commercially available. This method was also used to determine if substrate oxidation or product formation could be measured at a single wavelength where there was maximal diŠerence between the UV spectra of substrate and product.
The initial oxidation rates of 100 mM 6-MP catalysed by BMXO or partially puriˆed guinea pig liver fractions were measured up to 5 minutes at 350 nm by following the metabolite production using molecular oxygen as electron acceptor. The reactions were also monitored in the presence of AO inhibitors, 100 mM menadione, isovanillin and chlorpromazine, 18, [21] [22] [23] and XO inhibitor, allopurinol. 24) All reactions were carried out in 67 mM Sorenson's phosphate buŠer pH 7.0 containing 0.1 mM EDTA at 379 C.
HPLC analysis of 6-MP oxidation: HPLC analysis was carried out using a system supplied by Waters Associates, Northwich, Cheshire which consisted of a 510 pump, 710 B WISP automatic injector, LambdaMax 481 LC Spectrophotometer and 740 data module.
Chromatographic separation was achieved using a Spherisorb ODS2 5 mm (25 cm×4.6 mm, i.d.) column with a mBondapak C18 Guard-Pak insert and 0.5 mM ammonium acetate, pH 4.65 W 1.5z acetonitrile as the mobile phase at a ‰ow rate of 1.0 mL W min. The UV detection was at 335 nm.
6-MP (50 mM) was incubated with BMXO or partially puriˆed guinea pig liver fractions at 379 C in a total volume of 3 mL 67 mM phosphate buŠer pH 7.0 containing 0.1 mM EDTA up to 90 minutes. Incubations were performed in 10 mL closed vials which were placed in a shaking water bath and pre-warmed to 379 C. Aliquots (200 mL) were removed at 1, 5, 10, 15, 30, 45, 60 and 90 minutes and added to 100 mL 20z trichloroacetic acid to terminate the reaction. Samples were centrifuged in a Beckman bench-top microcentrifuge for 3-5 minutes at 3000 rpm and the supernatants were subsequently analysed by HPLC.
Incubations were also carried out in the presence of 100 mM of chlorpromazine, isovanillin and allopurinol.
Protein determination: Protein concentrations of partially puriˆed enzyme fractions were determined spectrophotometrically using a Pierce BCA Protein assay kit with bovine serum albumin as a protein standard. 25) Results Spectrophotometric measurement of 6-MP oxidation UV spectral analysis: The incubation of 100 mM 6-MP with 0.08 mg W mL bovine milk XO resulted in disappearance of absorption maximum of 6-MP spectrum at 321 nm and appearance of two new peaks at 349 nm and 241 nm within 30 minutes (Fig. 2) . Theˆnal spectrum was compared with that of 6-thioxanthine and those reported 13) for 8-oxo-6-MP and 6-thiouric acid. The spectrum of 8-oxo-6-MP contains two peaks at 312-313 nm and 330 nm 13) which indicates that this compound was not formed during 6-MP oxidation. However, the resulting spectrum was similar to those of 6-thioxanthine and 6-thiouric acid which have similar UV spectra 13) indicating that either of these two compounds could be the oxidation product. It was thus di‹cult to determine whether oxidation proceeded through an intermediate metabolite. When the experiment was repeated with lower XO concentration (0.016 mg protein W mL) to reduce the reaction rate, a similar proˆle was obtained. However, when the spectral changes of the oxidation of hypoxanthine by the same concentrations of BMXO were analysed, sequential formation of xanthine and uric acid could be clearly observed. This indicates that either a single oxidation product is formed from 6-MP or that oxidation of an intermediate, possibly 6-thioxanthine, is faster than its formation.
When 100 mM 6-thioxanthine was incubated with BMXO (0.08 mg protein W mL), the absorption maxima at 341 nm and 250 nm in the spectrum of 6-thioxanthine disappeared over º7 minutes and two new peaks appeared at 349 nm and 241 nm (Fig. 3) . Therefore, it seems more likely that 6-MP is converted to 6-thiouric acid via 6-thioxanthine in which the oxidation of 6-thioxanthine is faster than its formation. This will be further discussed later. As 6-MP is reported to be converted to 6-thiouric acid by BMXO, 1, 6, 13) it is likely that theˆnal oxidation product is 6-thiouric acid although the possibility of the metabolite being 6-thioxanthine cannot be discounted.
6-MP was slowly metabolised by high concentrations (1.7 mg protein W mL) of guinea pig enzyme. A slow reduction in the peak at 321 nm was observed with a shoulder appearing at 350 nm which could indicate the gradual formation of the same product as that formed in BMXO incubations. Therefore, it is possible to monitor the oxidation of 6-MP by following metabolite production at 350 nm where there is no interference from 6-MP.
Determination of initial oxidation rates: Table 1 summarises the inhibitory eŠects of 100 mM allopurinol, menadione and isovanillin on the initial oxidation rate of 100 mM 6-MP catalysed by BMXO or guinea pig liver fractions. As expected, the oxidation of 6-MP by BMXO was completely inhibited by 100 mM allopurinol. The reaction rate was increased in the presence of 100 mM menadione as this compound has a enhancement eŠect on XO activity. 21) However, with guinea pig enzyme fractions, 6-MP oxidation was only partially inhibited with 100 mM allopurinol with both menadione and isovanillin inhibiting the reaction by 40-50z. This indicates that both AO and XO are important in 6-MP oxidation in guinea pig liver. Menadione had a dual eŠect on the reaction; it initially reduced the oxidation rate but quietly caused an enhancement of the rate. The reaction was completely inhibited in the presence of both menadione (100 mM) and allopurinol (100 mM).
Oxidation of 6-MP by BMXO: When 50 mM 6-MP (R t ＝9.8 minutes) was incubated with BMXO (0.028 mg W mL), it almost completely disappeared within 90 minutes producing only a single peak (metabolite 1: M-1) with a retention time of 4.4 minutes. The retention time of 6-thioxanthine under these conditions was 11.5 minutes. Therefore, although the UV spectrum of the oxidation product of 6-MP was similar to that of 6-thioxanthine, the latter compound does not appear to be present in these incubations. Furthermore, when 50 mM 6-thioxanthine was incubated with BMXO (0.017 mg W mL), a product with the same retention time (R t ＝4.4 minutes) as M-1 was obtained. There was no 6-thioxanthine remaining after 15 minutes which indicates that 6-thioxanthine is oxidised by BMXO at a faster rate than 6-MP. Therefore, it appears that metabolite M-1 is not 6-thioxanthine. Zimm et al. have separated 6-thiouric acid, 6-MP and 6-thioxanthine using an isocratic HPLC system which is very similar to the HPLC system employed in the present study.
6) The chromatographic conditions developed by Zimm et al. consisted of a C-18 column (4.6 mm×25 cm), water (98.8z), acetonitrile (1z), and acetic acid (0.2z) as a mobile phase, ‰ow rate of 1.0 mL W min. Using this HPLC system, 6-thiouric acid, 6-MP and 6-thioxanthine chromotographed at 9.9, 12.5 and 16.8 minutes respectively. It, thus, appears that 6-MP is oxidised to 6-thiouric acid by BMXO. This is in agreement with those results indicating that 6-thiouric acid is the major metabolite following 6-MP administration. 6, 9) However, as stated above, only one peak (Rt＝4.4 minutes) was obtained from HPLC analysis of the oxidation of 6-MP by BMXO, whereas the conversion of 6-MP to 6-thiouric acid must proceed via an intermediate either 6-thioxanthine 6) or 8-oxo-6-mercaptopurine. 1, 9) The relative oxidation rate of 6-thioxanthine to 6-MP oxidation rate with BMXO is §8, whereas the oxidation rate of 8-oxo-6-mercaptopurine is only 1.2-fold higher than that of 6-MP reported by Krenitsky et al. 14) Taking into account the results obtained from UV spectral analysis of the reaction, it may be suggested that 6-MP is oxidised in a sequential pathway to 6-thiouric acid via 6-thioxanthine in which theˆrst reaction is the rate limiting step.
EŠect of XO and AO inhibitors on M-1 formation from 6-MP catalysed BMXO: The eŠect of 100 mM allopurinol, isovanillin and chlorpromazine on M-1 formation (expressed as peak height) from 50 mM 6-MP by BMXO has been tabulated in Table 2 . Allopurinol completely inhibited metabolite formation after 15 and 30 minutes. Chlorpromazine did not inhibit metabolite formation, wherase isovanillin caused a slight increase in the metabolite levels.
Oxidation of 6-MP by guinea pig liver fractions: Incubation of 50 mM 6-MP with guinea pig liver fractions (88±13 mg W mL, n＝4) generated a major metabolite which co-eluted with that found in BMXO incubations (Rt＝4.4 minutes). Two minor metabolites were also observed in some incubations after À60 minutes having Rt＝8.1 and Rt＝11.5 minutes; the latter one co-eluting with 6-thioxanthine. The concentration of 6-MP oxidised by guinea pig liver fraction (1.2 mg protein W mL) within 90 minutes was 29 mM.
EŠect of XO and AO inhibitors on M-1 formation from 6-MP catalysed by partially puriˆed guinea pig liver fractions: The eŠect of 100 mM allopurinol, isovanillin and chlorpromazine on the formation of M-1 (expressed as peak height) from 50 mM 6-MP by partial- ly puriˆed guinea pig liver fractions was determined ( Table 2) . Both XO and AO inhibitors reduced M-1 formation from 6-MP with allopurinol having the most signiˆcant eŠect. Allopurinol caused a higher inhibition (90-94z) of metabolite production at 15, 30 or 60 minutes than that of the the initial rate of oxidation measured spectrophotometrically (70z inhibition). This was expected as allopurinol is a suicide substrate of XO undergoing oxidation to oxipurinol, which binds tightly to reduced enzyme and thus causes potent inhibition. 26) In addition, AO also converts allopurinol to oxipurinol 27) and, thus, despite the inhibition of guinea pig liver XO, oxipurinol concentrations will increase with time.
Interestingly, the sum of the inhibition obtained with allopurinol and that with either of the aldehyde oxidase inhibitors exceeds 100z which indicates that there is more than one step involved in the production of M-1, which is thought to be 6-thiouric acid. As stated before, it is thought that 6-MP is oxidised to 6-thiouric acid via 6-thioxanthine. As allopurinol causes À90z inhibition of M-1 formation, it is proposed that XO is the predominant enzyme involved in the rate limiting step, i.e. production of 6-thioxanthine. Subsequent oxidation of 6-thioxanthine is thought to be catalysed by both molybdenum hydroxylases. If AO alone was responsible for the second oxidation step, AO inhibitors would cause build up of the intermediate, 6-thioxanthine. Inhibitor studies on the oxidation of 6-thioxanthine by guinea pig liver fractions would help to clarify this point. Figure 4 illustrates the proposed metabolic pathway for oxidation of 6-MP by guinea pig molybdenum hydroxylases in which theˆrst reaction is the rate limiting step.
Discussion
Although XO is considered as the major enzyme in the oxidation of 6-MP, there is some evidence which indicates that oxidation can also be catalysed by another source. In vivo studies have shown that there is a marked increase (À4-fold) in the amount of free 6-MP in the urine and 8-fold decrease in the amount of 6-thiouric acid excreted during theˆrst 12 hours following oral co-administration of 150 mg 6-MP and 75 W 300 mg allopurinol in man. In spite of this reduction in 6-thiouric acid excretion, the amounts of the metabolite detected in urine were still 39 and 14z of the control values with 75 and 300 mg allopurinol administration respectively.
28) The catabolic oxidative routes of 6-MP other than those catalyzed by XO have been attributed to the action of AO. 16) According to in vitro studies, 14) 6-MP is a substrate for AO, however, there is no direct in vivo evidence or detailed comparative studies indicating the involvement of molybdenum hydroxylases in the metabolism of this purine-based drug. Similar results with other compounds have been also published. Auscher et al. 29) have shown that, in vivo, the rate of the oxidation of allopurinol and its 6-mercapto analogues, thiopurinol, in one xanthinuric subject was as rapid as in controls. Interestingly, in vitro, the oxidation of both compounds was found to be extremely low. The involvement of AO in the oxidation of allopurinol in xanthinuric patients has been demonstrated, 30) and it is possible that the oxidation of thiopurinol observed by Auscher et al. 29) is due to AO activity. Kitchen et al. 31) have shown the oxidation of thioguanine which is not a 6-mercaptopurine Metabolism by Molybdenum Hydroxylases substrate for XO 14) following intravenous infusion of the drug. Based on some in vitro data, they attributed this catabolic pathway to aldehyde oxidase activity. Nevertheless, the in vivo contribution of AO to the oxidation of thiopurines is worthy of further investigation.
The major metabolite of 6-MP oxidation is 6-thiouric acid, however, this oxidative route passes via 6-thioxanthine or 8-hydroxy-6-mercaptopurine is not clear. According to some reports, 6-MP is converted to 6-thiouric acid through 6-thioxanthine, 6, 32) whereas, other authors have suggested that the oxidation intermediate is 8-hydroxy-6-mercaptopurine. 1, 9, 10, 17) The reason for this contraversy could be due in part to the diŠerence in metabolite proˆle between oral and intravenous administration of the drug. 16, 33) It is more likely that following oral administration, 6-MP is predominantely oxidized to 6-thiouric acid via 6-thioxanthine. Theˆrst step is catalyzed by XO, in particular in the gut. However, during intravenous infusion, which bypasses intestinal XO, either 6-MP or 6-thioguanine are mostly oxidized at 8 position. 34) Although these reactions could be oxidized by either XO or AO, the diŠerence in metabolite proˆle between oral and intravenus administration indicates that AO may be the major enzyme in 8-hydroxylation. 16) In addition, the results obtained in the present study and a higher capability of AO to produce 8-hydroxy metabolites from guanine and purine analogs compared with XO, 10, 23) provide more support for the involvment of AO in the matabolism of thioxanthine to thiouric acid as the major enzyme. This may be account for the results obtained by Keuzenkamp-Jansen et al. 32) These authors indicated that co-administration of allopurinol and high dose 6-MP infusion to patients with non-Hodgkin lymphoma resulted in a relatively higher plasma levels of 6-MP, 6-thioxanthine and methylpurine and a lower thiouric acid plasma level compared to those who did not receive allopurinol.
Conclusions
Although the conversion of 6-MP to thiouric acid could be either via 8-hydroxy-6-mercaptopurine or 6-thioxanthine, it appears that with both BMXO and partially puriˆed guinea pig liver molybdenum hydroxylases, 6-MP is oxidised to 6-thiouric acid via 6-thioxanthine in which theˆrst reaction is the rate limiting step. However, in order to clarify this proposed metabolic pathway, it seems necessary that the oxidation of both 8-oxo-6-mercaptopurine and 6-thioxanthine by guinea pig liver fractions are investigated in the absence and presence of speciˆc inhibitors of AO and XO.
With guinea pig liver fractions, XO is the major enzyme contributing to the conversion of 6-MP to 6-thioxanthine, whereas both molybdenum hydroxylases are involved in 6-thiouric acid formation from 6-thioxanthine.
